Highlights of This Issue 1023

SMALL MOLECULE THERAPEUTICS

1025  LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma Linlin Yang, Bhavna Kumar, Changxian Shen, Songzhu Zhao, Dukagjin Blakaj, Tianyun Li, Mitchell Romito, Theodoros N. Teknos, and Terence M. Williams

1036  SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer Shweta Joshi, Alok R. Singh, Kevin X. Liu, Timothy V. Pham, Muamera Zulcic, Dylan Skola, Hyun Bae Chun, Christopher K. Glass, Guillermo A. Morales, Joseph R. Garlich, and Donald L. Durden

1045  Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma Yang Yu, Yanling Zhao, Yihui Fan, Zhenghu Chen, Hui Li, Jiaxiong Lu, Kevin Guo, Sarah E. Woodfield, Sanjeev A. Vasudevan, Jianhua Yang, and Jed G. Nuchtern

1057  Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin Livia Elena Sima, Bakhtiyor Yakubov, Sheng Zhang, Salvatore Condello, Arabela A. Grigorescu, Nkechiyere G. Nwani, Lan Chen, Gary E. Schiltz, Constandina Arvanitis, Zhong-Yin Zhang, and Daniela Matei

LARGE MOLECULE THERAPEUTICS

1069  A Tumor-Peptide–Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy Carolin Heße, Sebastian Kollenda, Olga Rotan, Eva Pastille, Alexandra Adamczyk, Christina Wenzek, Wiebke Hansen, Matthias Eppler, Ian Buer, Astrid M. Westendorf, and Torben Knuschke

1081  A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy Pottayil G. Sasikumar, Raghuvire K. Ramachandra, Srinivas Adurthi, Amit A. Dhudashiya, Sureshkumar Vadlamani, Koteswararao Venula, Sriharibabu Vunnunu, Leena K. Satyam, Dodderi S. Saniulla, Krishnaprasad Subbarao, Rashmi Nair, Rajeev Shrimlal, Nagaraj Gowda, and Murali Ramachandra

1092  Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design Nam-Kyung Lee, Yang Su, Scott Bidlingmaier, and Bin Liu

1104  Discovery of a Novel EGFR-Targeting Antibody–Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies Kaijie He, Jianyan Xu, Jindong Liang, Jiahua Jiang, Mi Tang, Xin Ye, Zhebin Zhang, Lei Zhang, Beibei Fu, Yan Li, Chang Bai, Lianshan Zhang, and Weikang Tao

CANCER BIOLOGY AND TRANSLATIONAL STUDIES


1127  Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966 Tae Jin Lee, Mitra Nair, Yeshavanh Banasavadi-Siddegowda, Joseph Liu, Tejaswini Nallanagulagari, Alena Cristina Jaime-Ramirez, Jeffrey Yumhua Guo, Haroon Quadri, Jianying Zhang, Kurt H. Bockhorst, Manish K. Aghi, W. Shawn Carbonell, Balveen Kaur, and Ji Young Yoo
Table of Contents

1137 Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
Leslie Duplaquet, Martin Figae, Frédéric Lepêtre, Charline Frandemich, Céline Villenet, Shëhërazade Sebda, Naasir Sarafan-Vasseur, Mélanie Bénoîzëne, Audrey Vincenot, Cauter Goormachtigh, Laurence Vicoquat, Nathalie Rousseau, Ludivine Beausaire, Stéphanie Truant, Pierre Michel, Jean-Christophe Sabourin, Françoise Galateau-Salle, Marie-Christine Copin, Gérard Zalcman, Yvan De Launoit, Véronique Fafeur, and David Tulasne

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1149 Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis
Filip Janku, Eli L. Diamond, Aaron M. Goodman, Vaijayanthi Kandadai Raghavan, Tamara G. Barnes, Shumei Kato, Omar Abdel-Wahab, Benjamin H. Durham, Funda Meric-Bernstam, and Razelle Kurzrock

1158 Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer
Weiguo Cao, Yaping Xu, Lianpeng Chang, Yuhua Gong, Liren Li, Xianwei Mo, Xin Zhang, Guole Lin, Jiaolin Zhou, Dan Liu, Yuting Yi, Pingping Dai, Chenchen Zhu, Tao Liu, Yuxin Chu, Yanfang Guan, Yongsheng Chen, Jiyin Wang, Xuefeng Xia, Ling Yang, Xin Yi, and Yong Cheng

MODELS AND TECHNOLOGIES

1168 Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing
Jasmien Cornille, Agnieszka Wozniak, Haifu Li, Yannick Wang, Bram Boecks, Yemarneshet K. Gebreyohannes, Jasmien Wellens, Ulla Van Leeuwen, Daphne Hompes, Marguerite Stas, Friedell Sinnaeve, Hazem Wafa, Diether Lambrechts, Maria Debiec-Rychter, Raf Sciot, and Patrick Schöffski

RETRACTIONS

1179 Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P. Son, Elisa Attkisson, Paul Dent, Richard I. Fisher, Jonathan W. Friedberg, and Steven Grant

1180 Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P. Son, Hiral Patel, Derick Peterson, Elisa Attkisson, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent, and Steven Grant

1181 Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, and Steven Grant

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

Downloaded from mct.aacrjournals.org on July 26, 2021. © 2019 American Association for Cancer Research.
ABOUT THE COVER

The BCL-2/Xl pro-survival proteins compromise the effectiveness of cancer therapies. Here, Zoeller and colleagues provide in vivo evidence that neutralization of BCL-2/Xl via navitoclax/ABT-263 enhances the cytotoxic effectiveness of the HER2-targeted antibody-drug conjugate T-DM1. To assess the pathological responses associated with combined treatments, the authors performed specialized histological staining. The cover represents microscopic analysis of a Masson’s trichrome stained patient-derived xenograft treated with T-DM1 and navitoclax/ABT-263, and demonstrates substantial elimination of the tumor cells (red) and the emergence of a reactive stroma (blue). For more information, please see the article starting on page 1115.